# CART-19 Cells For MRD Positive CD19+ ALL

> **NCT03027739** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Fujian Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** CART-19

## Key facts

- **NCT ID:** NCT03027739
- **Lead sponsor:** Fujian Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-11
- **Primary completion:** 2019-12
- **Final completion:** 2020-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2017-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03027739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03027739, "CART-19 Cells For MRD Positive CD19+ ALL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03027739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*